EYPT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.01M

-91.32%

-0.748

+16.9%

400.00K

-98.36%

-0.672

+3.46%

400.00K

-92.5%

-0.680

-20%

Estimates Revision

The market is revising Downward the revenue expectations for EyePoint, Inc. (EYPT) for FY2025, with the revenue forecasts being adjusted by -11.95% over the past three months. During the same period, the stock price has changed by 20.59%.

Revenue Estimates for FY2025

Revise Downward

-11.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.41%

In Past 3 Month

Stock Price

Go Up

+20.59%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.60 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 16.400

Low

20.00

Averages

31.60

High

43.00

Current: 16.400

Low

20.00

Averages

31.60

High

43.00

Mizuho

Graig Suvannavejh

Outperform

maintain

2025-12-09

Reason

Mizuho

Graig Suvannavejh

Price Target

2025-12-09

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh notes that Ocular Therapeutix (OCUL) recently announced its intent to accelerate the approval timeline for its sustained-release tyrosine kinase inhibitor/TKI, Axpaxli, by submitting an NDA off its Phase 3 SOL-1 study. For EyePoint (EYPT), with its first Phase 3 LUGANO data for Duravyu expected in mid-2026, this potentially positions an Axpaxli approval ahead of that for Duravyu, in a scenario the firm previously haven't assumed. That said, in Mizuho's view, even if Ocular's more aggressive regulatory approach succeeds, the firm sees a number of issues for the company and its Axpaxli. With this in mind, and its greater comfort in EyePoint's more thorough Phase 3 approach for Duravyu, along with the strength of the prior Phase 2 Duravyu data, the firm sees minimal read-throughs for EyePoint and remains Outperform-rated on the stock.

Mizuho

Graig Suvannavejh

maintain

$33

2025-11-11

Reason

Mizuho

Graig Suvannavejh

Price Target

$33

2025-11-11

maintain

Reason

Mizuho analyst Graig Suvannavejh views the recent pullback in shares of EyePoint as a buying opportunity. The company's Q3 update was "fine," with no major changes for lead asset Duravyu, the analyst tells investors in a research note. The firm says Duravyu remains on track in its two Phase 3 programs. Mizuho recommends buying the stock with an Outperform rating and $33 price target.

Mizuho

Graig Suvannavejh

Outperform

maintain

$28 -> $33

2025-10-29

Reason

Mizuho

Graig Suvannavejh

Price Target

$28 -> $33

2025-10-29

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on EyePoint to $33 from $28 and keeps an Outperform rating on the shares.

Mizuho

Outperform

maintain

$26 -> $28

2025-08-14

Reason

Mizuho

Price Target

$26 -> $28

2025-08-14

maintain

Outperform

Reason

Mizuho raised the firm's price target on EyePoint to $28 from $26 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 results last week, where highlights included the previously announced enrollment completion in the second Phase 3 LUCIA study for Duravyu and, on Q2 results, lower OpEx. Mizuho continues to favor EyePoint in the highly competitive wet AMD/wAMD space, given its view that the company has a more robust set of Phase 2 data to support the potential of Duravyu; has a more straightforward pivotal Phase 3 clinical development program, one that is more representative of use in the real world; and finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved.

RBC Capital

Outperform

initiated

$28

2025-06-18

Reason

RBC Capital

Price Target

$28

2025-06-18

initiated

Outperform

Reason

Mizuho

Outperform -> NULL

downgrade

$30 -> $26

2025-05-16

Reason

Mizuho

Price Target

$30 -> $26

2025-05-16

downgrade

Outperform -> NULL

Reason

Mizuho lowered the firm's price target on EyePoint to $26 from $30 and keeps an Outperform rating on the shares following the Q1 report. The firm's focus remains on the clinical progress with lead asset Duravyu but it updated the company's model to reflect higher than expected expenses

Valuation Metrics

The current forward P/E ratio for EyePoint Inc (EYPT.O) is -5.96, compared to its 5-year average forward P/E of -3.38. For a more detailed relative valuation and DCF analysis to assess EyePoint Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.38

Current PE

-5.96

Overvalued PE

0.38

Undervalued PE

-7.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.37

Undervalued EV/EBITDA

-8.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

32.39

Current PS

0.00

Overvalued PS

129.32

Undervalued PS

-64.54

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2881.58% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 2881.58% over the last month.

Sold

Bought

EYPT News & Events

Events Timeline

No data

News

4.5

11-19Yahoo Finance

Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell

9.0

11-19Newsfilter

EyePoint Receives Favorable Endorsement from Independent Data Safety Monitoring Committee for Key Phase 3 Trials of DURAVYU™ in Wet Age-Related Macular Degeneration

9.5

11-09Yahoo Finance

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Predictions Have Deteriorated Slightly Following Its Recent Report

People Also Watch

Frequently Asked Questions

What is EyePoint Inc (EYPT) stock price today?

The current price of EYPT is 16.4 USD — it has increased 2.56 % in the last trading day.

What is EyePoint Inc (EYPT)'s business?

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

What is the price predicton of EYPT Stock?

What is EyePoint Inc (EYPT)'s revenue for the last quarter?

EyePoint Inc revenue for the last quarter amounts to 966.00K USD, decreased -90.82 % YoY.

What is EyePoint Inc (EYPT)'s earnings per share (EPS) for the last quarter?

EyePoint Inc. EPS for the last quarter amounts to -0.85 USD, increased 57.41 % YoY.

What changes have occurred in the market's expectations for EyePoint Inc (EYPT)'s fundamentals?

How many employees does EyePoint Inc (EYPT). have?

EyePoint Inc (EYPT) has 165 emplpoyees as of December 16 2025.

What is EyePoint Inc (EYPT) market cap?

Today EYPT has the market capitalization of 1.36B USD.